Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of endometrial cancer provides a clear picture of a disease that begins in the lining of the uterus, known as the endometrium. This page is designed for international patients and their families who are seeking reliable, medically‑accurate information about this common gynecologic malignancy. Each year, more than 380,000 women worldwide are diagnosed with endometrial cancer, making it the sixth most frequently occurring cancer among women.
In the following sections, you will find a thorough overview and definition of the condition, including its causes, risk factors, clinical presentation, diagnostic work‑up, treatment modalities, and long‑term care considerations. The information is aligned with the standards of Liv Hospital, a JCI‑accredited center that offers multidisciplinary, patient‑centered oncology services for visitors from around the globe.
Understanding the disease from an overview and definition perspective empowers patients to make informed decisions, collaborate effectively with their medical team, and navigate the journey toward recovery with confidence.
Endometrial cancer originates from the glandular cells of the uterine lining. It is classified primarily into two histologic types: endometrioid (type I) and non‑endometrioid (type II), each with distinct molecular profiles and clinical behavior. The disease typically presents in post‑menopausal women, although younger patients can be affected, especially when hereditary syndromes such as Lynch syndrome are present.
Key characteristics of endometrial cancer include:
Below is a concise table summarizing the main subtypes and their typical features:
Subtype | Typical Age | Hormonal Influence | Prognosis |
|---|---|---|---|
Type I (Endometrioid) | 55‑65 years | Estrogen‑driven | Generally favorable |
Type II (Serous, Clear Cell) | 65+ years | Less hormone‑related | More aggressive |
This overview and definition sets the foundation for understanding how the disease originates and why certain risk factors play a pivotal role.
Identifying the contributors to endometrial cancer is essential for prevention and early detection. The overview and definition of risk factors includes both modifiable and non‑modifiable elements:
Prevention strategies focus on lifestyle modifications and vigilant medical surveillance:
By understanding this overview and definition of risk, patients can collaborate with their physicians at Liv Hospital to implement personalized prevention plans.
Early recognition of endometrial cancer dramatically improves outcomes. The overview and definition of clinical presentation includes the following hallmark symptoms:
Diagnostic pathways at Liv Hospital begin with a thorough history and physical examination, followed by targeted investigations:
Test | Purpose | Typical Findings |
|---|---|---|
Transvaginal Ultrasound | Assess endometrial thickness | Thickness >5 mm in post‑menopausal women raises suspicion |
Endometrial Biopsy | Obtain tissue for histopathology | Presence of atypical cells or carcinoma |
Hysteroscopy | Direct visualization and targeted sampling | Visible lesions, polyps, or irregular mucosa |
This concise overview and definition of symptoms and diagnostic tools enables patients to seek timely evaluation, reducing the likelihood of advanced disease.
Accurate staging guides therapeutic decisions and prognostic counseling. The overview and definition of staging follows the FIGO (International Federation of Gynecology and Obstetrics) system, which categorizes disease from Stage I (confined to the uterus) to Stage IV (distant metastasis).
Key components of the staging work‑up include:
Below is a simplified staging table:
Stage | Description |
|---|---|
I | Limited to uterus (IA: ≤50% myometrial invasion; IB: >50% invasion) |
II | Spread to cervical stroma but not beyond uterus |
III | Local spread to adnexa, vagina, or pelvic lymph nodes |
IV | Distant metastasis (IVa: bladder or bowel; IVb: distant organs) |
Understanding this overview and definition of staging empowers patients to grasp the extent of disease and the rationale behind each therapeutic recommendation.
Management of endometrial cancer is multimodal, integrating surgery, radiation, chemotherapy, and hormonal therapy. The overview and definition of current treatment pathways includes:
Emerging therapies are expanding the therapeutic armamentarium:
Liv Hospital’s multidisciplinary team utilizes state‑of‑the‑art robotic surgery and precision radiation platforms, ensuring that each patient receives an individualized overview and definition of the most appropriate treatment strategy.
Survivorship care is a vital component of the overall disease journey. The overview and definition of post‑treatment follow‑up includes regular monitoring, management of treatment side effects, and psychosocial support.
Standard follow‑up schedule at Liv Hospital typically involves:
Support resources offered by Liv Hospital for international patients include:
This comprehensive overview and definition of survivorship emphasizes the importance of continuity of care, empowering patients to maintain quality of life after treatment.
Liv Hospital combines JCI accreditation, cutting‑edge technology, and a dedicated international patient program to deliver world‑class oncology care. Our multidisciplinary teams coordinate every step—from diagnosis to post‑treatment follow‑up—ensuring a seamless, patient‑focused experience for visitors from around the globe.
Ready to take the next step in your care journey? Contact Liv Hospital today to schedule a personalized consultation and discover how our expert team can support you through every phase of endometrial cancer treatment.
Send us all your questions or requests, and our expert team will assist you.
Endometrial cancer typically presents with abnormal uterine bleeding, which is the earliest and most frequent sign, particularly in post‑menopausal women. Other symptoms include persistent pelvic pain or pressure that does not improve with usual treatments, unexplained weight loss or fatigue in advanced disease, and changes in urinary or bowel habits if the tumor extends locally. Recognizing these signs early allows for prompt diagnostic evaluation, improving prognosis.
Obesity raises estrogen levels through peripheral conversion of androgens, creating a hormone‑driven environment that promotes endometrial proliferation. Unopposed estrogen therapy, early menarche, and late menopause also increase risk. Hereditary conditions such as Lynch syndrome and Cowden syndrome markedly raise lifetime risk. Metabolic disorders like diabetes and metabolic syndrome contribute via insulin resistance. Reproductive history factors, such as never having given birth (nulliparity) or using high‑dose estrogen fertility treatments, further elevate risk. Lifestyle modifications and genetic counseling can mitigate some of these risks.
The FIGO (International Federation of Gynecology and Obstetrics) staging system classifies endometrial cancer based on the extent of spread. Stage I disease is limited to the uterus, with subcategories IA and IB describing depth of myometrial invasion. Stage II involves cervical stromal invasion, Stage III indicates spread to adnexa, vagina, or pelvic lymph nodes, and Stage IV denotes distant metastasis to organs such as the bladder, bowel, or other distant sites. Accurate staging, achieved through pelvic MRI, CT, PET scans, and surgical pathology (including sentinel node mapping), is essential for selecting appropriate surgical, radiation, and systemic therapies, and for providing prognostic information to patients.
Standard management begins with surgical removal of the uterus, fallopian tubes, and ovaries (total hysterectomy with bilateral salpingo‑oophorectomy), often accompanied by sentinel lymph node assessment. Adjuvant radiation therapy—external beam radiotherapy (EBRT) and/or vaginal brachytherapy—reduces local recurrence risk. For high‑risk or advanced stages, chemotherapy (commonly carboplatin plus paclitaxel) is employed. Hormonal therapy with progestins is an option for low‑grade, hormone‑responsive tumors, especially when fertility preservation is desired. Emerging treatments include PD‑1 inhibitors (e.g., pembrolizumab) for MSI‑high tumors, mTOR inhibitors, anti‑angiogenic agents like bevacizumab, and personalized molecular‑guided clinical trials.
Post‑treatment surveillance at Liv Hospital typically involves a physical examination and pelvic imaging every 3‑6 months for the first two years, then annually. Blood tests, including tumor markers when appropriate, are performed yearly. Patients receiving hormonal therapy may need bone density assessments. Comprehensive survivorship programs also provide nutrition counseling, physiotherapy, mental‑health services, and multilingual patient navigation. Access to accommodation assistance, interpretation services, and global survivorship groups helps international patients maintain quality of life and adhere to follow‑up schedules.
BlogCancerFeb 19, 2026Patients often ask if they’ll be asleep during polyp removal. It depends on the polyp’s type an...
BlogCancerFeb 18, 2026Gynecological malignancies are cancers that affect the female reproductive system. They need accurate ICD-1...
BlogCancerFeb 18, 2026Diagnosis code C57.9 is a key ICD-10 code. It classifies malignant neoplasms of unspecified female genital ...
BlogCancerNov 03, 2025The Canadian Cancer Society says most women with uterine cancer get surgery. The surgery type depends on th...
BlogCancerNov 03, 2025Having a total hysterectomy is a big decision that affects a woman’s health. One worry is the chance ...
BlogCancerNov 03, 2025Many women feel anxious about medical imaging procedures. A transvaginal ultrasound is a tool used to see i...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24